S1605 HORIZON (OP-106): UPDATED EFFICACY AND SAFETY OF MELFLUFEN IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) REFRACTORY TO DARATUMUMAB (DARA) AND/OR POMALIDOMIDE (POM)

Authors :: M.V. Mateos
A. Paner
J. Harran
A. Alegre
J. Bladé
M. Cavo
C. Maisel
A. Oriol
A. Larocca
P. G. Richardson
Jeffrey A. Zonder
X. Leleu
Noemi Puig
H. Hassoun
H. Zubair
J. Harmenberg
Amitabha Mazumder
M. Norkin
S. Thuresson
Paula Rodriguez Otero
Source :: HemaSphere. 3:739
Publication Year :: 2019
Publisher :: Ovid Technologies (Wolters Kluwer Health), 2019.

Subjects :: Oncology
medicine.medical_specialty
Horizon (archaeology)
business.industry
Daratumumab
Hematology
Pomalidomide
Dara
medicine.disease
Refractory
Internal medicine
Relapsed refractory
medicine
business
Multiple myeloma
medicine.drug

Tools